Literature DB >> 1263131

Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.

E E Bagwell, T Walle, D E Drayer, M M Reidenbert, J K Pruett.   

Abstract

pan class="Chemical">N-acetylprocainamide (NAPA), a major metabolite of procainamide (PA) in man, has been reported recently to be biologically active. The present study compares the electrophysiological and antiarrhythmic effects of NAPA and PA and correlates their activity with plasma and tissue drug concentrations. In isolated canine Purkinje fibers, NAPA, in bath concentrations of 10 and 20 mg/l reduced automaticity and prolonged repolarization time. These effects were similar to those observed with similar concentrations of PA. Tissue concentrations of NAPA (77 +/- 2 mug/g) were significantly greater than those of PA (43+/-2 mug/g). Neither drug was metabolized by the fibers. In in vivo studies, NAPA (140-220 mg/kg) significantly suppressed the incidence of arrhythmias following coronary occlusion and digitalis intoxication. Similar protection was obtained with 40 to 60 mg/kg of PA. This difference in potency could not be attributed to differences in plasma and tissue concentrations of the drugs. These results show that NAPA is equally efficacious but less potent than PA as an antiarrhythmic drug in dogs.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1263131

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Metabolite formation pharmacokinetics: rate and extent of metabolite formation determined by deconvolution.

Authors:  M D Karol; S Goodrich
Journal:  Pharm Res       Date:  1988-06       Impact factor: 4.200

2.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 3.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

5.  Antiarrhythmic effects of Org 6001 in rats: correlation with plasma and tissue drug concentrations.

Authors:  K Kane; F McDonald; J Parratt; C Timmer; J Vink
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.